High-content micronucleus assay in genotoxicity profiling: initial-stage development and some applications in the investigative/lead-finding studies in drug discovery.

This article describes the first step toward full (that includes conditions for both absence and presence of metabolic activation) validation and drug discovery application of a 96-well, automated, high-content micronucleus (HCMN) assay. The current validation tests were performed using Chinese hamster ovary cells, in the absence of metabolic activation, against three distinct sets of drug-like compounds that represent all stages of a drug discovery pipeline. A compound categorization scheme was created based on quantitative relationships between micronucleus (MN) signals, cytotoxicity, and compound solubility. Results from initial validation compounds (n = 38) set the stage for differentiating overall positive and negative MN inducers. To delve deeper into the compound categorization process, a more extensive validation set, consisting of a larger set (n = 370) of "drug-like but less optimized" early-stage compounds, was used for further refinement of positive and negative compound categories. The predictivity and applicability of the assay for clinical stage compounds was ascertained using (n = 168) clinically developed marketed drugs or well-studied compounds. Upon full validation, a detailed analysis of results established five compound categories--NEG (negative), NEG/xx μM (negative up to the solubility limit of xx μM), WPOS (weak positive), POS (positive), and INCON (inconclusive). Furthermore, examples of lead-finding applications and ongoing investigative HCMN activities are described. A proposal is offered on how the HCMN assay can be positioned in parallel to the overall stage gates (e.g., scaffold selection, lead optimization, late-stage preclinical development) of drug discovery programs. Because of its greater throughput, 1-week turnaround time, and a substantially reduced (1-2 mg) requirement for compound consumption, the HCMN assay is appropriate for developing structure-genotoxicity relationships and for mechanistic genotoxicity studies. The assay does not replace the Organization for Economic Cooperation and Development-compliant, non-good laboratory practice in vitro MN test (e.g., slide-based MN test in TK6 lymphoblastoid cells) that is used for full characterization of lead candidates.

[1]  M. Fenech,et al.  HUMN project: detailed description of the scoring criteria for the cytokinesis-block micronucleus assay using isolated human lymphocyte cultures. , 2003, Mutation research.

[2]  Hans Bitter,et al.  Identification of a Kinase Profile that Predicts Chromosome Damage Induced by Small Molecule Kinase Inhibitors , 2009, PLoS Comput. Biol..

[3]  M. Fenech,et al.  Report from the In Vitro Micronucleus Assay Working Group , 2003, Mutation research.

[4]  J. Chao,et al.  Opposite roles of ERK and p38 mitogen-activated protein kinases in cadmium-induced genotoxicity and mitotic arrest. , 2001, Chemical research in toxicology.

[5]  T Sofuni,et al.  ICH-harmonised guidances on genotoxicity testing of pharmaceuticals: evolution, reasoning and impact. , 1999, Mutation research.

[6]  W. Piegorsch,et al.  The Ames test: the two-fold rule revisited. , 1996, Mutation research.

[7]  Haimei Huang,et al.  Involvement of calcium‐dependent protein kinase C in arsenite‐induced genotoxicity in chinese hamster ovary cells , 1997, Journal of cellular biochemistry.

[8]  Custer Ll,et al.  The role of genetic toxicology in drug discovery and optimization. , 2008 .

[9]  F. Romagna,et al.  Series: ‘Current issues in mutagenesis and carcinogenesis’ , 1988 .

[10]  R. D. Combes,et al.  Regulatory Genotoxicity Testing: A Critical Appraisal , 1995 .

[11]  A. Martelli,et al.  Update on genotoxicity and carcinogenicity testing of 472 marketed pharmaceuticals. , 2009, Mutation research.

[12]  M. Fenech,et al.  Cytokinesis-block micronucleus method in human lymphocytes: effect of in vivo ageing and low dose X-irradiation. , 1986, Mutation research.

[13]  K. Sweder,et al.  The role of genetic toxicology in drug discovery and optimization. , 2008, Current drug metabolism.

[14]  R. Walmsley.  GADD45a-GFP GreenScreen HC genotoxicity screening assay. , 2008, Expert opinion on drug metabolism & toxicology.

[15]  T. Jin,et al.  p53-Dependent but ATM-independent inhibition of DNA synthesis and G2 arrest in cadmium-treated human fibroblasts. , 2007, Toxicology and applied pharmacology.

[16]  R. Tice,et al.  Single cell gel/comet assay: Guidelines for in vitro and in vivo genetic toxicology testing , 2000, Environmental and molecular mutagenesis.

[17]  David Kirkland,et al.  Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens III. Appropriate follow-up testing in vivo. , 2005, Mutation research.

[18]  W. Hoffman,et al.  A protocol for the in vitro micronucleus test. II. Contributions to the validation of a protocol suitable for regulatory submissions from an examination of 10 chemicals with different mechanisms of action and different levels of activity. , 2002, Mutation research.

[19]  W. Hoffman,et al.  A protocol for the in vitro micronucleus test. I. Contributions to the development of a protocol suitable for regulatory submissions from an examination of 16 chemicals with different mechanisms of action and different levels of activity. , 2002, Mutation research.

[20]  H. Norppa,et al.  Induction of micronuclei by five pyrethroid insecticides in whole-blood and isolated human lymphocyte cultures. , 1995, Mutation research.

[21]  J W Green,et al.  A review of the genotoxicity of marketed pharmaceuticals. , 2001, Mutation research.

[22]  Sophie Malcomber,et al.  An assessment of the performance of an automated scoring system (Cellomics) for the in vitro micronucleus assay in CHO-K1 cells , 2007 .

[23]  P. Carmichael,et al.  Evaluation of an automated in vitro micronucleus assay in CHO-K1 cells. , 2007, Mutation research.

[24]  M. Aardema.  Introduction. Updated worldwide regulatory guidelines for genotoxicity testing. Workshop proceedings from the 1992 environmental mutagen scoiety meeting , 1993 .

[25]  Lutz Müller,et al.  Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens II. Further analysis of mammalian cell results, relative predictivity and tumour profiles. , 2006, Mutation research.

[26]  M. Fenech,et al.  The cytokinesis-block micronucleus technique: a detailed description of the method and its application to genotoxicity studies in human populations. , 1993, Mutation research.

[27]  P. Kasper,et al.  Human biological relevance and the use of threshold-arguments in regulatory genotoxicity assessment: experience with pharmaceuticals. , 2000, Mutation research.

[28]  J. T. Macgregor,et al.  Regulatory aspects of genotoxicity testing: from hazard identification to risk assessment. , 2008, Mutation research.

[29]  W. Suter.  Predictive value of in vitro safety studies. , 2006, Current opinion in chemical biology.

[30]  M. Fenech,et al.  HUman MicroNucleus project: international database comparison for results with the cytokinesis‐block micronucleus assay in human lymphocytes: I. Effect of laboratory protocol, scoring criteria, and host factors on the frequency of micronuclei , 2001, Environmental and molecular mutagenesis.

[31]  P. Repeto,et al.  A comparison of the in vitro Comet assay with the in vitro chromosome aberration assay using whole human blood or Chinese hamster lung cells: validation study using a range of novel pharmaceuticals. , 2002, Mutagenesis.

[32]  Technical aspects of automatic micronucleus analysis in rodent bone marrow assays , 1994, Cell Biology and Toxicology.

[33]  Lutz Müller,et al.  Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predictivity. , 2005, Mutation research.

[34]  F. Nesslany,et al.  A micromethod for the in vitro micronucleus assay. , 1999, Mutagenesis.

[35]  B. Burlinson,et al.  Use of the Miniscreen assay to screen novel compounds for bacterial mutagenicity in the pharmaceutical industry. , 1996, Mutagenesis.

[36]  E Zeiger,et al.  Strategy for genotoxicity testing: hazard identification and risk assessment in relation to in vitro testing. , 2007, Mutation research.

[37]  W Frieauff,et al.  Automatic analysis of the in vitro micronucleus test on V79 cells. , 1998, Mutation research.